An international team led by Icahn School of Medicine at Mount Sinai reported a fully human monoclonal antibody cocktail that provides complete protection against Nipah and Hendra virus infection in a hamster model, even when treatment is administered after infection begins. The findings were published in Science Translational Medicine. Researchers isolated two antibodies, 8G3 and 2A1, targeting the receptor binding protein and fusion protein, respectively, then combined them to achieve cross-species neutralization and to reduce immune-escape potential by applying independent mechanisms. Cryo-EM analysis supported a previously unrecognized neutralization strategy for 2A1, involving stabilization of a sugar-containing structure on the fusion protein. The work is framed as a step toward the first antibody-based therapeutics for Nipah and Hendra virus, highlighting how multi-epitope approaches can compensate for the scarcity of human survivor samples by enabling robust antibody discovery and testing.